Medindia

X

Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid

Wednesday, May 25, 2011 General News J E 4
Advertisement
- Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate(1,2)

Central phone:

+41 61 324 7944

Susanne Schaffert

+41 61 324 7944

North America:

Pierre-Michel Bringer

+41 61 324 1065

Richard Jarvis

+1 212 830 2433

Thomas Hungerbuehler

+41 61 324 8425

Jill Pozarek

+1 212 830 2445

Isabella Zinck

+41 61 324 7188

Edwin Valeriano

+1 212 830 2456

e-mail: investor.relations@novartis.com

e-mail: investor.relations@novartis.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
China Nepstar Chain Drugstore Reports First Quarte...
S
Health Diagnostic Laboratory, Inc. (HDL, Inc.) Ann...